Characterization of two T. gondii CK1 isoforms

Previous affinity chromatography experiments have described the unexpected binding of an isoform of casein kinase I (CK1) from Leishmania mexicana, Trypanosoma cruzi, Plasmodium falciparum and Toxoplasma gondii to an immobilized cyclin-dependent kinase (CDK) inhibitor (purvalanol B). In order to further evaluate CK1 as a potential anti-parasitic target, two T gondii CK1 genes were cloned by PCR using primers derived from a putative CK1 gene fragment identified from a T gondii EST database. The genes are predicted to encode a smaller polypeptide of 38 kDa (TgCK1 alpha) and larger 49 kDa isoform bearing a C-terminal extension (TgCK1 beta). Enzymatically active recombinant FLAG-epitope tagged TgCK1 alpha and TgCK1 beta enzymes were immuno-precipitated from transiently transfected T gondii parasites. While TgCK1 alpha expression was found to be cytosolic, TgCK1 beta was expressed predominantly at the plasma membrane. Deletion mapping showed that the C-terminal domain of TgCK1 beta confers this membrane-association. Recombinant TgCK1 alpha and TgCK1 beta isoforms were also expressed in E. coli and biochemically characterized. A 38 kDa native CK1 activity was partially purified from T gondii tachyzoites by ion-exchange and hydrophobic interaction chromatography with biochemical and serological properties closely resembling those of recombinant TgCK1 alpha. In contrast, we were not able to identify a native CK1 activity corresponding to the larger TgCK1 beta 49 kDa isoform in tachyzoite lysates. Purvalanol B and the related compound aminopurvalanol A selectively inhibit TgCK1 alpha, confirming the existence of potentially exploitable structural differences between host and parasite CK1 enzymes. Since the more cell-permeable aminopurvalanol also inhibits parasite growth, these results provide further impetus to investigate inhibitors of CK1 as anti-parasitic agents. Published by Elsevier B.V.